Compare PRIM & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRIM | BLCO |
|---|---|---|
| Founded | 1960 | 1853 |
| Country | United States | Canada |
| Employees | 18526 | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Ophthalmic Goods |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.9B |
| IPO Year | 2006 | 2022 |
| Metric | PRIM | BLCO |
|---|---|---|
| Price | $103.45 | $15.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $155.20 | $18.45 |
| AVG Volume (30 Days) | ★ 1.8M | 457.9K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 51.66 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $9.92 | $8.65 |
| Revenue Next Year | $8.80 | $5.59 |
| P/E Ratio | $383.81 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $71.84 | $11.44 |
| 52 Week High | $205.50 | $18.92 |
| Indicator | PRIM | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 48.73 |
| Support Level | $100.83 | $15.20 |
| Resistance Level | $122.33 | $16.41 |
| Average True Range (ATR) | 8.44 | 0.36 |
| MACD | 0.55 | -0.02 |
| Stochastic Oscillator | 9.42 | 55.66 |
Primoris Services Corp is a provider of critical infrastructure services operating mainly in the United States and Canada. The company provides a range of construction, maintenance, replacement, and engineering services. The Utilities segment operates throughout the United States and specializes in a range of services, including the construction and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communications systems. The Energy segment operates throughout the United States and Canada and specializes in a range of services that include engineering, procurement, construction, and maintenance services to various industries. The majority of the company's revenue is derived from the Energy segment.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.